Is PCOS Genetic? What a 23andMe “Higher Likelihood” Result and the 2025 Study of 94 Risk Loci Actually Mean

Is PCOS Genetic? What a 23andMe “Higher Likelihood” Result and the 2025 Study of 94 Risk Loci Actually Mean

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: Polycystic ovary syndrome (PCOS) is not caused by one gene. A 2025 study of more than 470,000 people found 94 separate spots in the genome linked to PCOS risk, 73 of them never reported before. PCOS affects an estimated 6-13% of women of childbearing age. It is not caused by weight alone — many patients, like the reader this article is written for, are not overweight. A 23andMe “higher likelihood” result reflects a score built by adding up small effects from many common gene changes across the genome. It is not a diagnosis and it does not replace bloodwork and an ultrasound. No drug is FDA-approved for PCOS itself, but letrozole, metformin, and birth control pills each treat one symptom under current guidelines.

What you’ll learn

• Why PCOS comes from many small genetic effects working together, not one broken gene, and what a 2025 study of 94 risk spots in the genome found
• How to turn a 23andMe DNA score into an honest number, not a guarantee
• What a real PCOS diagnosis requires that no DNA test can provide
• Why no drug is FDA-approved for PCOS, and what letrozole, metformin, and birth control actually do

PCOS Is Not One Gene: How a 2025 Study of 94 Risk Loci Rewrote the Genetics

Some genetic conditions come from a single broken gene passed down in a clear pattern. Cystic fibrosis works that way. PCOS does not.

PCOS is polygenic — a term that just means many genes, not one, add up to shape your risk. Many common gene changes each nudge risk up or down by a tiny amount. No single gene change causes PCOS on its own. Think of it less like a single light switch and more like a dimmer dial. Hundreds of tiny fingers rest on that dial, each one turning the light up or down just a little.

The clearest evidence for this came out in 2025. Researchers combined a Chinese study of 12,419 people with PCOS and 34,235 without it, plus a European study of up to 13,773 cases and 411,088 controls. Together, they found 94 separate locations in the genome tied to PCOS risk. 73 of those had never been reported before. The risk pattern looked similar across both Chinese and European ancestry groups. This suggests the same biology drives PCOS risk in both groups, rather than a quirk seen in just one population.

The study also pointed to what that biology actually is. Deeper analysis flagged genes involved in AMH (anti-Mullerian hormone) signaling. AMH is a hormone made by cells in the ovary that helps control egg development. The study also flagged the PPARG gene pathway, which helps control how the body responds to insulin. Both point to granulosa cells — the ovarian cells that nurture a developing egg — as a central player in PCOS.

A much older study backs up this many-gene picture. A 2006 Dutch study compared identical twins with fraternal twins and found PCOS traits were far more alike between identical twin pairs. That pattern put PCOS heritability at roughly 70%. That number sounds high, but heritability measures how much of the difference between people in a group traces back to genes. It does not predict any one person’s own odds.

It helps to compare PCOS with gene patterns readers may already know:

• Autosomal dominant (example: Huntington’s disease): one changed copy of a gene, from either parent, is enough to raise risk on its own.
• Autosomal recessive (example: cystic fibrosis): a person needs two changed copies, one from each parent, before the condition shows up.
• Polygenic (PCOS): no single copy and no single pair of copies does the job. Risk instead comes from adding up small nudges from many separate spots in the genome at once.

That is also why a DNA score like this works so differently from a single-gene test result. A single-gene test gives a yes-or-no answer about one specific gene change. A polygenic score instead adds up tiny statistical effects from many common gene changes — likely hundreds to thousands of them — into one combined probability shift. It was never built to point at a single cause, because for PCOS, no single cause exists to point at.

This distinction matters directly for a 23andMe report. The company’s “Health Predisposition” test for PCOS is not looking for one broken gene. It adds up small effects from a large number of common gene changes into one combined score, showing where you land compared with other people. A “higher likelihood” result means your combined score sits higher than average. It does not mean a specific gene broke.

Many readers think of genetics in terms of single-gene diseases. If that describes you, ask a genetic counselor to walk through how a DNA score like this differs from that model before your next appointment.

Section recap: PCOS comes from many small genetic effects, not one gene. A 2025 study found 94 risk spots shared across ancestries, pointing to AMH and insulin-related biology in the ovary. Heritability runs around 70% across a whole group of people, which a 23andMe DNA score reflects, but any one person’s score is not a diagnosis.

How Much Does a Higher Polygenic Score Actually Raise Your Risk?

A “higher likelihood” label can sound frightening without a number attached. Here is the number.

PCOS affects an estimated 6-13% of women of childbearing age, depending on which rules doctors use to diagnose it. That means somewhere between roughly 6 and 13 out of every 100 women of childbearing age already have PCOS, whether or not they carry a high DNA score. That is the starting point you are being compared against.

A high DNA score shifts your personal odds upward from that starting point. It does not set them to 100%. Each of the 94 gene changes found in the 2025 study nudges risk only slightly on its own. A polygenic score adds those small nudges together, so the combined shift is bigger than any one change alone, but it is still a probability, not a verdict. Many women with a high score never develop PCOS at all.

The opposite mistaken idea matters just as much. PCOS is often assumed to be a weight-driven condition. It is not. The National Institutes of Health notes that PCOS occurs across the full body-weight range, including in women who are not overweight. That includes the reader this article is written for: a woman with a clinical PCOS diagnosis and no extra weight. That combination can feel confusing if you were taught that PCOS and weight always go together.

What actually determines whether PCOS shows up in someone with a raised genetic risk is a mix of factors. Insulin resistance, body makeup, and even conditions before birth all interact with genetic risk. Genetics loads the dice. It does not roll them alone.

This is also why two sisters with similar DNA scores can end up with very different outcomes. One may develop clear PCOS symptoms in her teens. The other may never develop symptoms at all, even with a similar genetic background. Shared genes set a shared starting point. They do not set a shared ending point.

A useful comparison is a family history of heart disease. Knowing your father had a heart attack at 55 raises your own risk somewhat. It does not mean a heart attack is scheduled. The same logic applies to a PCOS DNA score: it is one input among several, not a countdown.

Bring your specific score, if you have one, to your OB-GYN or fertility specialist. They can weigh it against your actual period history and lab results, which matter far more for a diagnosis than a DNA score alone.

Section recap: PCOS affects about 6-13 out of 100 childbearing-age women overall. A high DNA score raises personal odds above that starting point but does not guarantee disease, and PCOS is not limited to women who are overweight.

DNA Test vs. Diagnosis: What 23andMe Can Tell You, and What Only an OB-GYN Can

A DNA report and a medical diagnosis answer two completely different questions. Confusing them is the single biggest source of unnecessary worry.

A 23andMe DNA score estimates genetic risk using a math-based model. It says nothing about whether you currently have irregular ovulation, extra male hormones, or unusual ovaries today. It is a look back at your DNA, not a look at your body right now.

A real PCOS diagnosis is entirely different. Under the 2023 International Evidence-based Guideline, used to update PCOS care in 196 countries, a doctor needs two of these three findings to diagnose PCOS:

• Ovulation problems — irregular or missing ovulation, usually shown by irregular periods.
• Extra male-pattern hormones — signs on exam or bloodwork, such as acne, excess hair growth, or a high testosterone level.
• Polycystic-looking ovaries — seen on an ultrasound scan of the ovaries.

Reaching that diagnosis takes real steps a DNA kit cannot copy. A doctor reviews your period history in detail. Bloodwork checks testosterone, plus the LH-to-FSH hormone ratio and AMH level. An ultrasound looks directly at the shape of the ovaries. Other conditions that look like PCOS, such as thyroid problems or a rare adrenal disorder, need to be ruled out along the way.

These three findings are often called the “Rotterdam” rules, named after the city where doctors first agreed on them. The 2023 guideline updated some technical details, such as which hormone tests count as reliable, but kept the same two-of-three structure. That matters: the diagnostic bar has not moved just because DNA tests became widely available to consumers.

There is also a practical, money difference. Direct-to-consumer (DTC) genetic tests like 23andMe are not a diagnostic tool and are not covered by health insurance. The real workup — bloodwork, ultrasound, and a specialist visit — is typically billable through US health insurance or a Canadian provincial health plan when a doctor orders it.

Picture it like a home pregnancy test versus a full prenatal ultrasound. One gives you a quick, useful signal. The other gives you the actual full picture, and only one of them is what your doctor bases a diagnosis on.

Say you received a 23andMe “higher likelihood” result and have not yet had bloodwork or an ultrasound. Treat that result as a reason to schedule an OB-GYN appointment, not as an answer in itself.

Section recap: A 23andMe score estimates genetic risk only. A real PCOS diagnosis needs two of three clinical findings — irregular ovulation, signs of extra male hormones, and a certain ovary appearance on ultrasound. Confirming those findings takes bloodwork, imaging, and a specialist visit.

Reading Your Result: Polygenic Score, Clinical Diagnosis, and What Stays Uncertain

Once you understand that a DNA score and a diagnosis are different things, the next question is what to actually do with either one.

Three things matter here, and they are not the same as each other. A DNA risk score is a probability shift, not a diagnosis. A clinical PCOS diagnosis comes only from the standard workup already described. And some findings, on either the genetic or clinical side, stay genuinely unclear.

A reassuring, low DNA score does not rule out PCOS. Current DNA scores, including 23andMe’s, explain only part of total inherited risk. They also leave out non-gene factors like insulin resistance and early-life conditions entirely. So a low score is not a green light to skip a workup if your periods are irregular or your hormone levels look off.

A high score works the same way in reverse. It does not confirm you currently have PCOS. Only the clinical findings can do that.

This gap between genetics and diagnosis explains something many patients find frustrating: for some people, getting a clear PCOS diagnosis can take time and more than one doctor’s visit. Early symptoms such as irregular periods can be mistaken for other, unrelated causes. Genetics alone cannot shortcut that process, because the diagnosis depends on ruling out look-alike conditions and confirming a specific combination of findings, not on a single test result.

Think of a DNA score as a smoke detector with a sensitivity dial, not a fire report. It tells you the alarm is more or less likely to go off. It does not tell you whether there is currently a fire.

The right move with any DTC genetic result, high or low, is to bring it to an OB-GYN or fertility specialist for context. Do not use it to self-diagnose or delay a workup you would otherwise pursue based on your actual symptoms.

Section recap: A DNA score, a clinical diagnosis, and an uncertain finding are three different things. Neither a high nor a low DNA score changes what the standard clinical workup can tell you, and genetics alone does not shorten the path to a clear diagnosis.

Prevention and Surveillance: What Actually Lowers Your Long-Term Risk

You cannot change the genetic risk you were born with. You can change how closely it gets watched.

There is no way to prevent the underlying gene-based risk for PCOS itself. That is true whether your score came back high or low. What the 2023 International Evidence-based Guideline actually recommends instead is regular monitoring for the conditions PCOS raises your risk of over time.

Three areas get specific attention:

• Diabetes risk — regular checks for type 2 diabetes and prediabetes, since insulin resistance is a common feature of PCOS. The CDC recommends routine metabolic screening for exactly this reason.
• Heart risk — checking cholesterol and blood pressure regularly.
• Uterus-lining risk — for anyone who goes long stretches without ovulating, since skipped periods over years can let the lining of the uterus build up unchecked. This raises the risk of uterine cancer.

Diet and exercise support is a first step too, but the guideline is specific about what that means. It calls for planned diet and exercise help fit to the person, not a one-size-fits-all weight-loss rule for every patient no matter their starting weight or symptoms. That difference matters especially for patients who are not overweight, where a generic weight-loss recommendation would miss the point entirely.

The practical value of a high DNA score, then, is not prevention in the usual sense. It is an earlier and steadier reason to ask for metabolic screening, rather than waiting until symptoms force the issue.

None of this requires waiting for a formal PCOS diagnosis first. Irregular periods, insulin resistance, or a family history are all reasonable grounds to ask for a fasting glucose or A1C test at your next check-up. This holds regardless of what a DNA score shows.

A useful comparison is a family history of glaucoma. You cannot prevent the genetic risk. You can get your eye pressure checked more often because of it, catching problems early instead of late.

Ask your primary care doctor or OB-GYN how often you should be screened for diabetes and heart-related risk factors, based on your personal and family history. Do not assume a one-size-fits-all schedule applies.

Section recap: Genetic risk for PCOS cannot be prevented. Its complications can be caught earlier through regular diabetes, heart, and uterus-lining health checks, alongside diet and exercise support fit to the person rather than a one-size-fits-all weight-loss rule.

Current Treatment Options for PCOS, and Why None Is FDA- or Health Canada-Approved for PCOS Itself

Here is a fact that surprises many readers: no drug currently carries an FDA approval — or a matching Health Canada approval — specifically for PCOS as a disease. Every medicine used for PCOS is either approved for a different condition and used off-label, or used under current guidelines for one specific symptom.

For fertility, the guideline picture has shifted in recent years. Letrozole is now the guideline’s first choice for causing ovulation in PCOS-related infertility. Letrozole briefly lowers estrogen — doctors call this type of drug an aromatase inhibitor — which prompts the brain to release more of the hormone that helps an egg mature and release.

A large randomized trial of PCOS patients trying to conceive found much higher live-birth rates with letrozole than with clomiphene citrate, an older ovulation drug. A separate Cochrane review of many trials backs up that same finding, though the trial evidence quality ranged from low to moderate.

The table below shows the regulatory status of the main drugs used for PCOS symptoms in both the United States (FDA) and Canada (Health Canada):

Drug	FDA status (US)	Health Canada status	How it’s used for PCOS
Letrozole	Approved for breast cancer	Not detailed in the regulatory sources reviewed here	First-line, off-label, to cause ovulation
Clomiphene citrate	Approved 1967 for ovulation problems	Sold in Canada as Serophene from 1985 and again from 1991; both brand versions have since been discontinued (2014 and about 2017)	Second-line, to cause ovulation
Metformin	Approved 1994 for type 2 diabetes	Approved 1995 as Glucophage; still sold in Canada today	Off-label, for insulin resistance
Combination birth control pills	Multiple brands approved for cycle control	Multiple brands approved in Canada (not detailed here)	First-line, for irregular periods and extra male hormones
Spironolactone	Approved for blood pressure	Not detailed in the regulatory sources reviewed here	Off-label, for excess hair growth and acne
Eflornithine cream (Vaniqa)	Approved 2000-07-07 for facial hair	Approved 2005; withdrawn from the Canadian market in 2007 and no longer sold there	Reduces unwanted facial hair

That last point matters for Canadian readers in particular. Eflornithine cream (Vaniqa) and the brand-name clomiphene products above were once authorized for sale in Canada. They are no longer sold there, even though the U.S. versions remain available. A Canadian reader looking for either drug by its original Canadian brand name may find it is simply off the market, not that it was never approved.

One more area is worth flagging honestly. GLP-1 drugs, a newer class of medicines for weight and blood sugar, are drawing interest for PCOS-related insulin resistance. As of this article’s writing, that use is not an FDA-approved PCOS use in the US or an approved PCOS use in Canada. It should be discussed directly with a treating doctor before trying it for this purpose.

None of this means PCOS is untreatable, and none of it means pregnancy is off the table. It means treatment targets each symptom one at a time, using drugs built and approved for other purposes, guided by current evidence.

Think of PCOS treatment like a toolbox built from borrowed tools. Each one does its specific job well. None of them was manufactured with a “PCOS” label on the box.

Ask your fertility specialist which of these options fits your specific goals — regular periods, clearer skin, or a pregnancy timeline. The right combination differs from patient to patient.

Section recap: No drug is FDA-approved — or Health Canada-approved — for PCOS itself. Letrozole is now first-line for causing ovulation, ahead of clomiphene, though some Canadian brand versions of older PCOS-related drugs like clomiphene and Vaniqa are no longer sold in Canada. Metformin and combination birth control pills address insulin resistance and period symptoms, and GLP-1 drugs remain a new, not yet approved, option for this use.

Family Risk: What an Elevated Score Means for Your Sister or Daughter

Because PCOS is polygenic rather than a single dominant or recessive gene, it does not spread through families the way BRCA1 or Lynch syndrome do. That difference changes what family guidance should actually look like.

There is no clean, single-gene-change test to run on a sister or daughter the way there is for a known BRCA1 change in a family. Instead, first-degree relatives of someone with PCOS carry a clearly higher, but not fixed, chance of developing it themselves. That higher risk reflects shared genes and a shared environment together, not one inherited change passed down a family tree.

The real advice here is awareness, not testing. If your sister or daughter has irregular periods, acne, or excess hair growth, that combination is worth mentioning to her own doctor, along with your family history. A DTC DNA test is not recommended as a screening tool for relatives. A low DNA score in a sister or daughter would not rule out future PCOS, since current scores explain only part of total risk.

There is also no step to take for a child, before symptoms appear, based on a DNA result alone. Unlike some single-gene conditions, there is no early medicine or procedure a young relative should start purely because a family member carries a high score. The right move is watching for symptoms and mentioning family history at routine check-ups, not ordering a DNA test for a child or teenager who has no symptoms yet.

A board-certified genetic counselor is the right resource if a family member wants a deeper explanation of what a high score does and does not mean for relatives. You can find one through the National Society of Genetic Counselors at NSGC.org.

A helpful way to frame this for family members: think of it as a weather advisory for the household, not an individual forecast. It tells relatives to pay closer attention, not that a storm is guaranteed for any one of them.

Section recap: PCOS has no clean family-testing chain because it is polygenic, not single-gene. First-degree relatives carry clearly higher but not fixed risk, and the right response is watching for symptoms and mentioning family history to a doctor, not DTC genetic screening.

GINA, Insurance Gaps, and the Emotional Weight of a Fertility-Linked Result

Beyond the biology, a PCOS genetic result raises two very different concerns: legal protection, and how the whole process feels.

In the United States, the Genetic Information Nondiscrimination Act, or GINA, passed in 2008. It blocks health insurers and employers from using a genetic test result, including a 23andMe DNA score, against you. Employers cannot use it in hiring or firing decisions, and health insurers cannot use it to deny coverage or raise rates. GINA’s job rules apply to employers with 15 or more workers, and its insurance rules apply to group and individual health plans.

Two protections apply, depending on where you live:

• United States (GINA, 2008) — blocks health insurers and employers from using a genetic result, but does not cover life, disability, or long-term-care insurance.
• Canada (Genetic Non-Discrimination Act, 2017) — makes it a criminal offense to require genetic testing, or disclosure of results, as a condition of receiving goods or services, including insurance. Canada’s Supreme Court upheld the law as constitutional in 2020.

The emotional side deserves equal attention. PCOS carries a real emotional and social weight tied to fertility uncertainty and visible symptoms like acne and excess hair growth. For some patients, that weight also includes a diagnosis that takes a while to reach. The 2023 International Evidence-based Guideline itself calls for emotional-health screening — checking for anxiety, depression, and body-image concerns — as part of routine PCOS care, not as an afterthought.

A slow path to diagnosis can make all of this harder. For some patients, seeing more than one doctor before getting a clear answer can feel discouraging, right when they most need to be heard. A DNA result that arrives in the middle of that search can feel like the first real answer. As this article has stressed throughout, it is only one small piece of the full picture.

If the emotional weight of a fertility-linked diagnosis feels heavy, that reaction is common and worth naming out loud, not something to push through alone. Getting mental-health support alongside medical care is a normal, guideline-backed part of PCOS care, not a separate or lesser concern.

Think of GINA and Canada’s law as a good umbrella that still leaves your shoes wet in a sideways storm. It covers a lot, but not everything, so it pays to know exactly where the coverage stops before you need it.

Talk to your OB-GYN or a mental-health provider about both the medical and emotional sides of your diagnosis. You do not need to sort out the insurance questions or the emotional impact on your own.

Section recap: GINA (US) and the Genetic Non-Discrimination Act (Canada) both block genetic discrimination in health insurance and employment, but neither covers life, disability, or long-term-care insurance. PCOS also carries a real emotional and social weight that current guidelines treat as a standard part of care, not an extra.

Frequently asked questions

Will I get PCOS if my 23andMe result shows a higher likelihood?

No test can answer that for certain. A higher-likelihood result means your DNA score sits above average, based on many common gene changes added together. It is not a diagnosis. PCOS affects about 6-13 out of 100 childbearing-age women overall, and many women with a high score never develop it. Only a clinical workup — period history, bloodwork, and ultrasound — can confirm a diagnosis.

Will my children inherit PCOS from me?

Not in a simple, single-gene sense. PCOS is polygenic, so children inherit a mix of many small genetic effects, not one clear-cut gene change. There is no reliable test to run on a daughter before she has symptoms. The most useful step is mentioning your family history at her own checkups if she later develops irregular periods, acne, or excess hair growth.

Can a genetic PCOS result affect my health or life insurance?

In the US, GINA blocks health insurers from using a genetic result, including a 23andMe score, to deny coverage or raise rates. It does not cover life, disability, or long-term-care insurance, where a result could still be considered in most states. In Canada, the federal Genetic Non-Discrimination Act blocks insurers from requiring genetic testing or results as a condition of coverage.

Does PCOS mean I can’t get pregnant?

No. PCOS is one of the most common causes of infertility, but it is treatable. Letrozole is now the guideline’s top drug for causing ovulation in PCOS-related infertility, with strong trial evidence behind it, ahead of the older drug clomiphene citrate. Many women with PCOS do become pregnant, often with the help of these treatments.

Should I get a second opinion or bring my DNA result to a specialist?

Yes. A DNA score is a research-based estimate, not a diagnosis. Bring any DTC genetic result to your OB-GYN or a fertility specialist so they can weigh it against your actual symptoms and lab results. A board-certified genetic counselor can also help you understand exactly what the score does and does not tell you.

Summary

PCOS is a polygenic condition — shaped by many genes, not one. A 2025 study found 94 separate risk spots shared across Chinese and European groups, pointing to AMH signals and insulin-related biology in the ovary as key mechanisms. It affects an estimated 6-13% of childbearing-age women, and it is not limited to women who are overweight, correcting a common mistaken idea.

A 23andMe DNA score estimates genetic risk using many common gene changes added together. It cannot replace the standard clinical diagnosis, which needs two of three specific findings confirmed through bloodwork and ultrasound. No drug is FDA-approved — or Health Canada-approved — for PCOS itself, but letrozole, metformin, and birth control pills each address one symptom under current guidelines. Some older Canadian brand versions of these drugs are no longer sold there. Letrozole is now preferred over clomiphene for fertility treatment.

Family risk is real but does not follow a clean single-gene pattern, so awareness and clinical follow-up matter more than DTC testing for relatives. GINA and Canada’s Genetic Non-Discrimination Act both offer real, if incomplete, legal protection, and the emotional weight of a fertility-linked diagnosis deserves the same attention as the medical side. Bring any genetic result to an OB-GYN or fertility specialist rather than interpreting it alone.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. Multi-ancestry genome-wide association meta-analysis of polycystic ovary syndrome identifies 94 independent risk loci and implicates granulosa-cell and AMH/PPARG biology. Nature Genetics. 2025 Nov;57(11):2669-2681. PMID 41188533. DOI 10.1038/s41588-025-02393-x. https://pubmed.ncbi.nlm.nih.gov/41188533/
2. National Institute of Child Health and Human Development (NICHD), National Institutes of Health. Polycystic Ovary Syndrome (PCOS): Condition Information. https://www.nichd.nih.gov/health/topics/pcos
3. Centers for Disease Control and Prevention. PCOS (Polycystic Ovary Syndrome) and Diabetes. https://www.cdc.gov/diabetes/risk-factors/pcos-diabetes.html
4. Genetic Information Nondiscrimination Act of 2008, Public Law 110-233. US Equal Employment Opportunity Commission. https://www.eeoc.gov/genetic-information-discrimination
5. Genetic Non-Discrimination Act, S.C. 2017, c. 3. Government of Canada, Justice Laws Website. https://laws-lois.justice.gc.ca/eng/acts/g-2.5/
6. Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. Journal of Clinical Endocrinology & Metabolism. 2006. https://pubmed.ncbi.nlm.nih.gov/?term=Vink+heritability+polycystic+ovary+syndrome+twin+family+2006
7. Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome (PPCOS II trial). New England Journal of Medicine. 2014. DOI 10.1056/NEJMoa1313517. https://doi.org/10.1056/NEJMoa1313517
8. US Food and Drug Administration, Drugs@FDA approval database (clomiphene citrate 1967, metformin 1994, eflornithine hydrochloride cream/Vaniqa 2000-07-07), and Health Canada Drug Product Database / regulatory decision records (clomiphene as Serophene, authorized 1985 and 1991, both brand versions since discontinued; metformin as Glucophage, authorized 1995, still marketed; eflornithine cream/Vaniqa, authorized 2005, withdrawn from the Canadian market 2007). https://www.accessdata.fda.gov/scripts/cder/daf/
9. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Human Reproduction. 2023 Sep 5;38(9):1655-1679. PMID 37580037. DOI 10.1093/humrep/dead156. https://pubmed.ncbi.nlm.nih.gov/37580037/
10. Teede HJ, Tay CT, Laven JJE, et al. International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2023, co-published summary. European Journal of Endocrinology. 2023 Aug 2;189(2):G43-G64. PMID 37580861. DOI 10.1093/ejendo/lvad096. https://pubmed.ncbi.nlm.nih.gov/37580861/
11. Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2013. DOI 10.1210/jc.2013-2350. https://doi.org/10.1210/jc.2013-2350
12. American College of Obstetricians and Gynecologists. Polycystic Ovary Syndrome: Clinical guidance and patient FAQ. https://www.acog.org/womens-health/faqs/polycystic-ovary-syndrome-pcos
13. Cochrane Database of Systematic Reviews. Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome. https://www.cochranelibrary.com/cdsr/reviews
14. Polycystic Ovarian Syndrome. StatPearls Publishing, NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK459251/

---

Last updated: 2026-09-07

Author: Yu Mizuno (Editor-in-Chief, non-physician), GeneLumen editorial team. This article aggregates 14 sources from peer-reviewed medical literature and public health agencies (tier 1 = 8 / tier 2 = 6), including NIH (NICHD), CDC, the US Food and Drug Administration, Health Canada, the US Equal Employment Opportunity Commission, the Government of Canada, Nature Genetics, the 2023 International Evidence-based Guideline (Human Reproduction / European Journal of Endocrinology), ACOG, Cochrane, and PubMed-indexed publications.

Editorial responsibility: Yu Mizuno, research editor. Not a physician, medical geneticist, or genetic counselor.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911.

Related: Genetic Diseases category

🌐 日本語版 (Japanese version)